Polypharmacy among anabolic-androgenic steroid users: a descriptive metasynthesis by Sagoe, D et al.
Sagoe, D and McVeigh, J and Bjornebekk, A and Essilfie, M-S and
Andreassen, CS and Pallesen, S (2015)Polypharmacy among anabolic-
androgenic steroid users: a descriptive metasynthesis. Substance Abuse
Treatment, Prevention, and Policy, 10 (12).
Downloaded from: http://e-space.mmu.ac.uk/624816/
Version: Published Version
Publisher: BioMed Central
DOI: https://doi.org/10.1186/s13011-015-0006-5
Usage rights: Creative Commons: Attribution 4.0
Please cite the published version
https://e-space.mmu.ac.uk
REVIEW Open Access
Polypharmacy among anabolic-androgenic steroid
users: a descriptive metasynthesis
Dominic Sagoe1*, Jim McVeigh2, Astrid Bjørnebekk3, Marie-Stella Essilfie4, Cecilie Schou Andreassen1,5
and Ståle Pallesen1
Abstract
Background: As far as we are aware, no previous systematic review and synthesis of the qualitative/descriptive
literature on polypharmacy in anabolic-androgenic steroid(s) (AAS) users has been published.
Method: We systematically reviewed and synthesized qualitative/descriptive literature gathered from searches in
electronic databases and by inspecting reference lists of relevant literature to investigate AAS users’ polypharmacy. We
adhered to the recommendations of the UK Economic and Social Research Council’s qualitative research synthesis
manual and the PRISMA guidelines.
Results: A total of 50 studies published between 1985 and 2014 were included in the analysis. Studies originated from
10 countries although most originated from United States (n = 22), followed by Sweden (n = 7), England only (n = 5),
and the United Kingdom (n = 4). It was evident that prior to their debut, AAS users often used other licit and illicit
substances. The main ancillary/supplementary substances used were alcohol, and cannabis/cannabinoids followed
by cocaine, growth hormone, and human chorionic gonadotropin (hCG), amphetamine/meth, clenbuterol,
ephedra/ephedrine, insulin, and thyroxine. Other popular substance classes were analgesics/opioids, dietary/nutritional
supplements, and diuretics. Our classification of the various substances used by AAS users resulted in 13 main groups.
These non-AAS substances were used mainly to enhance the effects of AAS, combat the side effects of AAS, and
for recreational or relaxation purposes, as well as sexual enhancement.
Conclusions: Our findings corroborate previous suggestions of associations between AAS use and the use of
other licit and illicit substances. Efforts must be intensified to combat the debilitating effects of AAS-associated
polypharmacy.
Keywords: Anabolic-androgenic steroids, Ergogenic aids, Doping, Human enhancement drugs, IPEDs,
Polypharmacy, Stacking, Metasynthesis, Qualitative research
Introduction
Anabolic-androgenic steroid(s) (AAS) refer to testosterone
and its synthetic derivatives mainly used nonmedically for
enhancing muscle growth and strength, boosting physical
activity or sports performance, and for aesthetic purposes
as well as for enhancing psychological well-being [1]. AAS
are typically used in phases referred to as ‘cycles’: ‘on cycles’
referring to specific periods when the users administer AAS
and ‘off cycles’ referring to an AAS-free phase intended to
prevent tolerance towards AAS, lessen the possibility of side
effects, and allow recovery of natural hormonal functioning.
During ‘on cycles’ users sometimes combine different
injectable and oral AAS. This phenomenon is referred to as
‘steroid stacking’ or simply ‘stacking’ [2].
There is also a trend referred to as ‘blast and cruise’ or
‘bridging’ – a continuous ‘on cycle’ whereby many users
never go off AAS but alternate between periods of high
dose intake during a ‘blast’ phase, and low dose intake dur-
ing a ‘cruise’ phase. Another way of administering AAS is
called ‘blitz-cycles’, which implies rapidly changing AAS
with the aim of preventing tolerance and androgen receptor
down-regulation. Moreover, many users complement AAS
use or stacking with the use of other substances. In this re-
spect, AAS use has been found to be associated with the
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use of both licit and illicit substances in systematic reviews
of predominantly quantitative literature [3,4].
It has been noted that one of the major drawbacks to
successful AAS interventions is public health officials’ fail-
ure to recognize AAS users’ extensive pharmacological
regimen [2]. A synthesis of the qualitative or descriptive lit-
erature on polypharmacy by AAS users is, both from a
clinical and research perspective, important in order to in-
crease the understanding of the polypharmacy often associ-
ated with AAS use. Such a literature review and synthesis
is also valuable in terms of the development and strength-
ening of AAS use and harm reduction interventions as
such investigation will deepen existing knowledge on the
various substances used and the specific function they
serve, which in some cases deviates significantly from their
formal medical indications. Furthermore, results of such
investigation would complement evidence emanating from
a systematic review of mostly quantitative evidence [3]
in the effort to elucidate the phenomenon of polysub-
stance use by AAS users. However, as far as we are
aware, a systematic review and synthesis of the qualita-
tive or descriptive literature on polypharmacy by AAS
users has not been published.
Against this backdrop, we conducted the first system-
atic review and synthesis of the qualitative or descriptive
studies presenting data on the use of other licit and illicit
substances among AAS users. The research questions
guiding the present study were: (a) what substances do
AAS users report consuming prior to their AAS debut?
(b) what ancillary or supplementary substances do AAS
users report using? and (c) what reasons do AAS users
assign for using these substances?
Method
Search strategy and inclusion criteria
We searched in PsycINFO, PubMed, ISI Web of Science,
and Google Scholar for literature. For searches in PubMed
and ISI Web of Science, ‘anabolic steroid’, ‘doping’, and
‘performance enhancing drug’, were each combined with
‘interview’, ‘focus group’, and ‘qualitative’. These combina-
tions were not practical in PsycINFO and Google Scholar
as they produced voluminous redundant hits. Thus, ‘ana-
bolic steroid + doping + performance enhancing drug +
interview + focus group + qualitative’ was used in searches
in PsycINFO and Google Scholar. From a total of 10,106
hits, 7,720 articles were assessed after the removal of dupli-
cates. We also inspected references of relevant studies and
searched in online databases and websites.
This search yielded 15 new articles. Based on titles and
abstracts, 106 full-text papers were retrieved for screening
after initial evaluation of the 7,735 papers. After screening
of the 106 full-text papers, 79 papers were deemed relevant
for inclusion. Thus, of the 79 papers scrutinized, 50 studies
satisfied the following inclusion criteria: (a) studies used
qualitative approaches (interviews, focus groups, or case
studies) in data collection, (b) studies delineated or de-
scribed licit and illicit substances used nonmedically by
AAS users, and (c) studies were published in English.
We again inspected the characteristics of extracted stud-
ies for similarities to curb duplicate extraction and synthe-
sis. The literature search was completed in June 2014. The
literature search strategy adhered to Shaw et al.’s [5] rec-
ommendations for qualitative literature search as well as
the Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [6]. Figure 1 presents
the literature search process.
Data extraction and synthesis
The first author conducted the study scrutiny and selection.
Analysis of the studies was conducted using Smith et al.’s
[7] Interpretative Phenomenological Analysis (IPA). Each
full-text paper was regarded as a transcript. The first author
(DS) read through the full-text papers several times, gaining
an overall sense of the themes in the studies through this
process. These themes were then highlighted. Using a stan-
dardized data extraction form, the first author and another
reviewer independently extracted the following data from
the included studies: author name and publication year,
country, study type, type of AAS users involved in the
study, and recruitment site or mode. To assess the
quality of the extraction, we calculated inter-reviewer
reliability for the two reviewers in SPSS version 20
(IBM Corp.) [8]. DS then independently coded the
full-text papers by substance used and reason(s) or
motive(s) for use. Study characteristics are presented
in Table 1. We have presented all the studies that fall
under each substance.
Classification of substances
We sought to classify the various non-AAS substances
used by AAS users into meaningful groups. First, SP pro-
vided a functional categorization of the substances. Ac-
knowledging that some AAS users self-administer these
substances for purposes contrary to their conventional use,
DS built on SP’s classification by allocating the substances
into SP’s groups based on motives for use as presented by
users in the literature. For substances for which motive for
use was not delineated in the literature, DS grouped them
based on Evans-Brown et al.’s [2] classification of human
enhancement substances and a classification by the
Norwegian Institute of Public Health [59]. JM inspected
the grouping and provided further advice. Next, DS allo-
cated substances that at this stage could not be allocated
into groups based on the three previous methods by refer-
ring to Medscape Drug Reference and Wikipedia [60]. We
reached consensus on the classification through further
review and discussion.
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Results and discussion
Description of studies and inter-reviewer reliability
A total of 50 studies were included in the metasynthesis.
Participants’ ages ranged from 14 [34] to 66 years [51].
The year of publication of the studies ranged from 1985
[55] to 2014 [12,13,30]. Studies originated from 10 coun-
tries with the highest number from the United States
(n = 22), followed by Sweden (n = 7), England only (n = 5),
the United Kingdom (n = 4), Australia (n = 3), and
Scotland only (n = 2). Additionally, one study originated
from Canada, Denmark, France, Iran, and Wales only re-
spectively. One study [16] originated from Australia,
Canada, and USA while another described the sample
as European [43]. Thirty studies used interviews
[10-12,17,19-22,24,27,28,30-32,34-38,40-43,45,47,48,51,53,
55,58], seven were case studies [9,23,29,39,49,50,57], one
used interviews and focus groups [13], and twelve
[14-16,19,25,26,33,44,46,52,54,56] used interviews sup-
ported by a questionnaire. For the studies that used both
interviews and questionnaires, we relied on the qualitative
or descriptive results generated from the interviews. There
was very good agreement (Kappa = 0.82, p < 0.001) between
the two reviewers [61]. Through further analysis and dia-
logue agreement was reached on discrepant extractions.
Substances used prior to AAS initiation
Before their AAS use debut, some users had experimented
with or were regular users of other substances. This was
presented by ten studies [17,21,24,26-29,34,47,53]. The most
prominent of these substances were alcohol, amphetamine,
cannabis, and cocaine. Others were analgesics/opioids, her-
oin, stimulants, and dietary/nutritional supplements such as
creatine, and protein powder as well as other unspecified
licit and illicit substances (see Table 2).
In Kanayama et al.’s study [26]:
[AAS] users displayed much higher rates of other illicit
drug use, abuse, or dependence than non-users, with
use of other illicit substances almost always preceding
first use of AAS (p. 77).
A recent study by Cornford, Kean, and Nash [13] also
highlights heroin use as a precursor to AAS use:
A quick way to make yourself look healthy, isn’t it,
without being embarrassed about being on heroin [is
to use AAS], do you know what I mean. It [heroin]
does take a lot of your confidence away don’t it and
like I say, especially, I lose weight pretty fast when I’m
on heroin, do you know what I mean. It [AAS use] is
a quick way to just make yourself look healthy again,
isn’t it (p. 2).
Furthermore, it is important to note that our data also
suggested that AAS use may precede the use of other
substances for some individuals. In Hoff ’s study [24]:
Figure 1 Flow diagram of systematic literature search.
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Table 1 Characteristics of qualitative/descriptive studies presenting data on polypharmacy in AAS users
First author, year,
reference
Country Study type AAS users Recruitment site/mode Non-AAS substances ever used
Ahlgrim 2009 [9] USA Case study 41-year-old male former
bodybuilder
Hospital Captopril, carvedilol, digoxin, furosemide, growth hormone,
hydrochlorothiazide, spironolactone, torsemide,
Angoorani 2009
[10]
Iran Interview 843 bodybuilders aged 16 to
40 years
Gymnasium Amphetamine
Bilard 2011 [11] France Interview 203 bodybuilders Voluntary Beta-2-agonists, cannabinoids, glucocorticosteroids,
peptide hormones
Chandler 2014 [12] UK Interview 8 persons Online forums, syringe
exchange center
Aromatase inhibitors, clenbuterol, 2,4-dinitrophenol, clomiphene,
diuretics, ephedrine, growth hormone releasing peptide, growth
hormone, human chorionic gonadotropin (hCG), insulin-
like growth factor 1, insulin, mechano growth factor, melanotan,
mephedrone, tamoxifen, thyroid hormones, viagra®/cialis®
Cornford 2014 [13] England Interview and
focus group
30 males aged 20 to 40 years Syringe exchange center Heroin
Davies 2011 [14] England Interview and
questionnaire†
9 male bodybuilders Gymnasium Creatine, dietary supplements
Dunn 2010 [15] Australia Interview and
questionnaire†
70 persons Community Alcohol, cannabis, cocaine, ecstasy, gamma hydroxybutyrate,
hallucinogens, inhalants, ketamine, amphetamine
Filiault 2010 [16] Australia, Canada,
USA
Interview and
questionnaire†
16 gay male athletes aged 18
to 52 years
Gay sporting groups Creatine, dietary supplements, growth hormone, recovery drinks
Fudala 2003 [17] USA Interview 7 males aged 22 to 33 years Gymnasium and community Alcohol, analgesics, cannabis, cocaine, stimulants, growth
hormone, human chorionic gonadotropin (hCG), insulin-like
growth factor 1
Gårevik 2010 [18] Sweden Interview 45 offenders; mean age 30 years Police station Amphetamine, anti-oestrogens, benzodiazepines, cannabis,
clenbuterol, cocaine, diazepam, ephedra, ephedrine, growth
hormone, human chorionic gonadotropin (hCG), heroin,
insulin, sildenafil
Goldfield 2009 [19] Canada Interview and
questionnaire†
8 female bodybuilders Gymnasium Diuretics, laxatives
Gruber 1998 [20] USA Interview 19 female weightlifters Gymnasium Clenbuterol, ephedrine, narcotics/other drugs
Gruber 1999 [21] USA Interview 5 female bodybuilders Gymnasium Alcohol, cannabis, cocaine, clenbuterol, dietary supplements, other
drugs, other performance-enhancing drugs
Gruber 2000 [22] USA Interview 25 female weightlifters; mean
age 31 years
Gymnasium Aminogluthemide, amphetamine, caffeine, clenbuterol, diuretics,
ephedrine, hydroxyl butyrate, human chorionic gonadotropin
(hCG), growth hormone, laxatives, nalbuphine, other opioids,
tamoxifen, thyroid hormones, yohimbine
Hegazy 2013 [23] USA Case study 28-year-old male Clinic Alcohol, amphetamine, opioids
Hoff 2012 [24] Sweden Interview 11 male (10 powerlifters, 1
weightlifter)
Swedish Sports
Confederation
Alcohol, amphetamine, cocaine, narcotics, others
Hope 2013 [25] England and
Wales
Interview and
questionnaire†
340 injecting drug users Syringe exchange center 2,4-dinitrophenol, alcohol, amphetamine, anti-oestrogens,
clenbuterol, cocaine, ephedrine, erythropoietin, growth
hormone, human chorionic gonadotropin (hCG), insulin,
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Table 1 Characteristics of qualitative/descriptive studies presenting data on polypharmacy in AAS users (Continued)
melanotan II, nalbuphine, thyroid hormones, diuretics, PDE5i,
viagra®/cialis®
Kanayama 2003
[26]
USA Interview and
questionnaire†
48 male weightlifters; mean age
29 years
Gymnasium and sports
supplement store
Alcohol, cannabis, cocaine, opioids, other narcotics/illicit drugs
Kanayama 2003
[27]
USA Interview 24 male drug users; mean age
32 years
Clinic Alcohol, cocaine, heroin, nalbuphine, opioids, oxycodone
Kanayama 2009
[28]
USA Interview 62 male weightlifters Gymnasium and sports
supplement store
Alcohol, cannabis, cocaine, opioids, other performance-
enhancing drugs, other drugs
Katz 1990 [29] USA Case study 23-year-old male bodybuilder Gymnasium Alcohol, cocaine
Kimergård 2014
[30]
England and
Wales
Interview 24 males aged 21 to 61 years;
mean age 34 years
Gymnasium, prison, steroid
clinic and charity, syringe
exchange centre
Amphetamine, clenbuterol, growth hormone, ephedrine, human
chorionic gonadotropin (hCG), insulin, melanotan II, sildenafil,
tamoxifen
Klötz 2010 [31] Sweden Interview 33 male prisoners aged 21 to
52 years
Prison Antidepressants, anti-oestrogen, aspirin®, benzodiazepines,
caffeine, cannabis, central stimulating drugs, clenbuterol, creatine,
diuretics, ephedrine, Gamma hydroxybutyrate, insulin-like growth
factor 1, insulin, genotropine, muscle relaxing drugs, myoblast,
opiates, other drugs, potency increasing drugs,
somatotropine, testicular function recovering hormones
Korkia 1993 [32] England, Scotland,
and Wales
Interview 110 persons (13 female) aged 16
to 63 years
Clinic, gymnasium, syringe
exchange centre
Antibiotics, corticosteroids, dietary supplements, diuretics,
esiclene, human chorionic gonadotropin (hCG), oestrogen-
antagonist drug, growth hormone, thiomucase, thyroxine
Korkia 1996 [33] England Interview and
questionnaire†
15 females; mean age 28 years Not specified Clenbuterol, growth hormone, nolvadex, nubain®,
thiomucase, triacana
Kusserow 1990
[34]
USA Interview 72 (6 female) persons (mostly
adolescents); 14 to 25 years; mean
age 20 years
Not specified Alcohol, blood pressure regulators, ‘downers’, estrogen
inhibitors, growth hormone, cannabis, Recreational substances/drugs, ‘uppers’
Larance 2008 [35] Australia Interview 60 males aged 17 to 59 years Gymnasium, internet
forums, supplement shops
Anti-oestrogenic agents, aspirin®, benzodiazepines, caffeine,
cannabis, cocaine, clenbuterol dehydroepiandrosterone (DHEA),
diuretics, ecstasy, hallucinogens, heroin, human chorionic
gonadotrophin (hCG), ephedrine, growth hormone,
inhalants, insulin-like growth factors, insulin, meth/amphetamine,
thyroxine
Lenehan 1996 [36] England Interview 386 persons aged 17 to 56 years;
mean age 28 years
Gymnasium Clenbuterol, corticosteroids, diuretics, growth hormone, human
chorionic gonadotropin (hCG), thyroxine, insulin-like growth
factor 1, nubain®, tamoxifen
Lundholm 2010
[37]
Sweden Interview 924 (20 female) persons Prison Benzodiazepines, cannabis, cocaine, meth/amphetamine, opiates
Malone 1995 [38] USA Interview 77 (6 female) powerlifters and
bodybuilders
Gymnasium Alcohol, cocaine, hallucinogen, opioids, sedatives, stimulants,
tetrahydrocannabinol, tobacco
McBride 1996 [39] Wales Case study 3 males: 1 AAS dealer and roofer
aged 27 years, 1 bodybuilder
aged 22 years, and 1 gym owner
aged 26 years)
Not specified Amphetamine, cannabis, clenbuterol, human chorionic
gonadotropin (hCG), nalbuphine, tamoxifen, temazepam
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Table 1 Characteristics of qualitative/descriptive studies presenting data on polypharmacy in AAS users (Continued)
McKillop 1987 [40] Scotland Interview 8 male bodybuilders aged 17 to
32 years
Gymnasium Furosemide, thiazides, thyroxine, human chorionic gonadotropin
(hCG)
Moss 1992 [41] USA Interview 50 male bodybuilders Gymnasium Clomiphene citrate, human chorionic gonadotropin (hCG)
Moss 1993 [42] USA Interview 30 male bodybuilders Gymnasium Clomiphene citrate, human chorionic gonadotropin (hCG)
Pappa 2012 [43] Europe Interview 9 athletes aged 19 to 26 years Community via snowball
sampling
Analgesics, amphetamine, caffeine, cannabis, dietary supplements,
diuretics, erythropoietin.
Perry 1990 [44] USA Interview and
questionnaire†
20 male weightlifters aged 18
to 28 years
Gymnasium Human chorionic gonadotropin (hCG)
Perry 2003 [45] USA Interview 10 male weightlifters aged 21
to 40 years
Gymnasium Aspirin®, caffeine, clomiphene, creatine, dietary supplement,
ephedrine, glutamine, liothyronine, protein powder, yohimbine
Peters 1997 [46] Australia Interview and
questionnaire†
100 persons (6 female) aged 18
to 50 years
Advertisements, gymnasium,
interviews, radio, sports shops
and associations, syringe
exchange centre
Alcohol, aminogluthimide, amphetamine, antibiotics, beta
blockers, caffeine, cannabis, chromium picolinate, clenbuterol,
cocaine, daonil®, dietary supplement, diuretics, ecstasy, ephedrine,
growth hormone, human chorionic gonadotropin (hCG),
hydroxocobal amin, insulin-like growth factor 1, insulin, oestrogen
antagonist, pregnyl®, proviron®, teroxin (T3), thyroxine
Pope 1988 [47] USA Interview 41 male bodybuilders and
footballers
Gymnasium Alcohol, cannabis, cigarettes, cocaine, human chorionic
gonadotropin (hCG)
Pope 1994 [48] USA Interview 88 athletes; mean age 26 years Gymnasium Alcohol, cannabis, tobacco
Rashid 2000 [49] USA Case study 40-year-old male Clinic Cocaine, cannabis, ‘uppers’, ‘downers’, lysergic acid diethylamide
(LSD)
Schäfer 2011 [50] Denmark Case study 26-year-old male bodybuilder Clinic Erythropoietin
Silvester 1995 [51] USA Interview 22 former athletes aged 36 to
66 years
Not specified Growth hormone
Skårberg 2007 [52] Sweden Interview and
questionnaire†
18 male drug users; mean age
35 years
Clinic Alcohol, narcotics/other drugs
Skårberg 2008 [53] Sweden Interview 6 drug users (2 female) Clinic Alcohol, amphetamine, analgesics, anti-catabolics, anti-oestrogens,
aspirin®, benzodiazepines, bronchodilators, buprenorphine,
caffeine, cannabis, cocaine, codeine, conjugated linoleic acid,
creatine, dietary supplements, ecstasy, ephedra, ephedrine, growth
hormone, Herbal products, insulin growth factor 1, insulin, protein
powder, testosterone releasers
Skårberg 2009 [54] Sweden Interview and
questionnaire†
32 male drug users Clinic Alcohol, amphetamine, anti-oestrogen (clomid), analgesics,
anti-acne drug, anti-catabolics, anti-depressants, anti-hypertensive
drugs, anti-oestrogens, benzodiazepines, bronchodilators, cannabis,
cocaine, creatine, dietary supplements, diuretics, ephedrine, fat-loss
agents, gamma hydroxybutyrate, growth hormone, heroin, insulin,
insulin-like growth factor 1, levodopa, muscle oil (synthol),
non-steroidal anti-inflammatory drugs, opioid, plant steroid
compounds, protein powder, stimulants, testosterone boosters,
thyroid hormone
Strauss 1985 [55] USA Interview 10 weight-trained female
athletes; mean age 33 years
Personal contact Acetaminophen, aspirin®, benoxaprofen, Ben-Gay®, caffeine,
calcium, choline and inositol, dietary supplements, dimethyl
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Table 1 Characteristics of qualitative/descriptive studies presenting data on polypharmacy in AAS users (Continued)
sulfoxide, codeine, electrolyte solution, epinephrine, furosemide,
growth hormone, levodopa, lidocaine, naproxen, oxycodone
hydrochloride, phenylbutazone, piroxicam, potassium, suntan
pills, thyroglobulin, vitamins
Tallon 2007 [56] Scotland Interview and
questionnaire†
30 males aged 18 to 43 years;
mean age 27 years
Gymnasium Alcohol, cannabis, cocaine, clenbuterol, dietary supplements,
diuretics, ecstasy, growth hormone, insulin, tamoxifen
Wilson-Fearon
1999 [57]
England Case study 29-year-old bodybuilder Not specified Clenbuterol, dietary supplements, diuretics, growth hormone,
human chorionic gonadotropin (hCG), thiomucase
Wines 1999 [58] USA Interview 11 weightlifters (5 female) aged
19 to 42 years
Gymnasium Alcohol, buprenorphine, heroin, hydrocodone, nalbuphine, other
drugs
†We relied on the qualitative results generated from the interview.
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Respondent 8 reported using narcotics after he had
started using AAS. In this case, alcohol and drug abuse
cannot explain why he started doping [using AAS].
However, AAS use seems to have led him into drug use
and criminality in order to finance his extensive AAS use
and investment in elite powerlifting. This respondent
became aggressive and violent when he combined AAS
and alcohol. Due to these side effects he changed from
alcohol to cocaine as his primary social drug when he
was on AAS (p. 63).
Use of supplementary/ancillary substances
AAS users often engaged in stacking and the use of vari-
ous licit and illicit substances during their ‘on cycles’ as
previously shown. For instance, in a study by McBride
[39], “…Mr B had initially used nalbuphine in conjunc-
tion with anabolic steroids, clenbuterol, ephedrine, and
tamoxifen, all to aid bodybuilding” (p. 69). Indeed, in a
study [46] of 100 AAS users: “A number of other drugs
were used in addition to AAS as part of their training
routine by 49% of the sample” (p. 49).
The most popular supplementary/ancillary substances
declared by AAS users in multiple studies were: alcohol,
amphetamine/meth, aspirin®, caffeine, cannabis/cannabi-
noids, clenbuterol, clomiphene citrate, cocaine, codeine, cre-
atine, ephedra/ephedrine, erythropoietin, furosemide, gamma
hydroxybutyrate (GHB), growth hormone, heroin, human
chorionic gonadotropin (hCG), insulin, insulin-like growth
factor 1 (IGF-1), melanotan, nalbuphine/nubain®, protein
powder, tamoxifen, thyroxine, and tobacco. Other popular
classes of substances presented were analgesics/opioids,
anti-oestrogens, benzodiazepines, dietary/nutritional supple-
ments, diuretics, hallucinogens, and stimulants (see Table 3).
Lifetime polypharmacy
We also investigated lifetime use of other substances by
AAS users. The most popular substances (declared in
multiple studies) were: 2,4-dinitrophenol (DNP), alcohol,
aminogluthimide, amphetamine/meth, aspirin®, buprenorphine,
caffeine, cannabis/cannabinoids, clenbuterol, clomiphene
citrate, cocaine, codeine, creatine, ephedra/ephedrine,
erythropoietin (EPO), furosemide, gamma hydroxybutyrate
(GHB), growth hormone, heroin, human chorionic
gonadotropin (hCG), insulin, insulin-like growth factor 1
(IGF-1), ketamine, levodopa, lysergic acid diethylamide
(LSD), melanotan, nalbuphine/nubain®, oxycodone, protein
powder, sildenafil/viagra®/cialis®, tamoxifen, thiomucase,
thyroxine, and yohimbine. Other popular classes of
substances presented were analgesics/opioids, antibiotics,
anti-catabolics, anti-oestrogens, benzodiazepines, blood
pressure regulators, bronchodilators, dietary/nutritional
supplements, diuretics, hallucinogens, inhalants, stimulants,
and testosterone releasers/boosters.
Of the above substances, the most commonly identified
in studies include alcohol, cannabis/cannabinoids, cocaine,
growth hormone, human chorionic gonadotropin (hCG),
amphetamine/meth, clenbuterol, ephedra/ephedrine, insulin,
and thyroxine. Commonly identified classes of substances
include analgesics/opioids, dietary/nutritional supplements,
diuretics, and anti-oestrogens (see Table 3).
Groups of non-AAS substances used by AAS users
Our classification of the various substances used by AAS
users resulted in 13 main groups: analgesics/non-steroidal
anti-inflammatory drugs/opioids, anti-oestrogens, cardio-
vascular drugs, central nervous system depressants, cen-
tral nervous system stimulants, cosmetic drugs, dietary/
Table 2 Non-AAS substances used before AAS use debut, reason(s)/motive(s) for use, and studies
Substance Reason(s) for use Studies (First author, reference)
Alcohol Better sleep and relaxation Fudala [17]; Gruber [21]; Hoff [24]; Kanayama [26]; Katz [29];
Kusserow [34]; Perry [47]; Skårberg [53]
Amphetamine Boosting training, alertness,
psychological wellbeing
Hoff [24]; Skårberg [53]
Analgesics/opioids† Pain relief Kanayama [26]
Cannabis NS Fudala [17]; Hoff [24]; Kanayama [26]; Kusserow [34]; Perry [47]
Cocaine NS Fudala [17]; Gruber [21]; Kanayama [26]; Katz [29]; Perry [47]
Creatine Boosting training Skårberg [53]
Dietary/nutritional supplements† Boosting training, energy Skårberg [53]
Heroin NS Cornford [13]
Protein powder Boosting training Skårberg [53]
Stimulants† NS Kusserow [34]
Other IPEDs, licit and illicit substances NS Gruber [21]; Hoff [24]; Kanayama [27,28]; Perry [47]
IPEDs: Image and performance-enhancing drugs.
NS: Not specified.
†Substance class - not specified.
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nutritional supplements, diuretics, fat burning/weight loss
drugs, muscle/strength-enhancement hormones, non-hor-
mone muscle/strength-enhancement drugs, recreational
substances/drugs, and sexual enhancement drugs (see
Table 4). These groups of substances are briefly discussed
below.
Analgesics/non-steroidal anti-inflammatory drugs/opioids
These drugs include aspirin®, codeine, and oxycodone. This
group of drugs was used for relieving inflammation, pain,
and fever emanating from exercise, sports participation or
the recreational and occupational activities of AAS users.
Anti-oestrogens
Anti-oestrogens include aminogluthimide, clomiphene,
and tamoxifen. These drugs were used for reducing the
oestrogen-like side effects of AAS use such as preventing
gynecomastia. They were also used for endurance, im-
proved testosterone production, and burning body fat.
Cardiovascular drugs
These drugs such as captopril, carvedilol, and digoxin
were used for improved functioning of the cardiovascular
system such as lowering blood pressure and reducing the
risk of myocardial infarction, as well as burning body fat.
Central nervous system depressants
Examples of depressants are buprenorphine, hydrocodone,
and oxycodone. The purposes for which these drugs were
used were improved sleep, relaxation, and elevation of mood.
Central nervous system stimulants
Stimulants including epinephrine, amphetamine/metham-
phetamine, and yohimbine were used for alertness, boost-
ing training, burning body fat, increased aggression and
strength (including sexual), and psychological wellbeing.
Cosmetic drugs
Cosmetic or aesthetic drugs such as esiclene, melanotan
II, and thiomucase were used in order to deal with acne,
and for: inflammatory effects on smaller muscles, skin
tanning, and a leaner physique thus enhancing physical
appearance.
Dietary/nutritional supplements
These supplements such as calcium, glutamine, and po-
tassium were consumed to provide essential nutrients to
supplement the diet and combat the risk of illness.
Diuretics
Diuretics such as furosemide, hydrochlorothiazide, and
spironolactone were used for combating side effects of
AAS use such as water retention, together with masking
the use of AAS and other doping agents.
Fat burning/weight loss drugs
These drugs include 2,4-dinitrophenol (DNP), conju-
gated linoleic acid, and teroxin (T3) and were used for
suppression of appetite, increased metabolism, and re-
duced absorption of body fat as a means to burning
body fat and losing weight.
Muscle/strength-enhancement substances
Two types of muscle/strength-enhancement substances
were presented in the literature: hormones and non-
hormones. Examples of muscle/strength-enhancement
hormones are growth hormones, growth hormone re-
leasing peptide (GHRP), and insulin. Non-hormone
muscle/strength-enhancement drugs include clenbuterol
used by some in an attempt to enhance the size and
structure of muscles, as well as boosting strength.
Recreational substances/drugs
Recreational substances/drugs such as cannabis/cannabinoids,
cocaine, and lysergic acid diethylamide (LSD) were used to
alter experiences, elevate mood, and create psychological
wellbeing as well as for relaxation.
Sexual enhancement drugs
These drugs such as phosphodiesterase-5 inhibitors
(PDE5i), melanotan II, and sildenafil were used for deal-
ing with testicular atrophy, improved sexual desire or
arousal as well as erectile functioning.
In sum, the above groups of substances were used to en-
hance the effects of AAS, combat the side effects of AAS,
and for recreational or relaxation purposes, as well as sex-
ual enhancement. It is important to note that there is
overlap between some of the groups. For instance, some
central nervous system depressants may be misused for
promoting sleep as well as their analgesic properties.
Again, some muscle/strength-enhancement hormones are
used for direct muscle enhancing properties and others
for counteracting shutdown of endogenous testosterone
production. Additionally, some of the substances are used
for multiple purposes. For instance, melanotan II is used
for tanning the skin and also as self–treatment for erectile
dysfunction resulting from long-term AAS use. Others
may use melanotan II to self-treat specific conditions such
as rosacea or fibromyalgia and others may use melanotan
for the self-reported weight loss effects due to appetite
suppression. It is also important to note that some of the
alleged properties or uses are not scientifically well docu-
mented such as the use of insulin for burning body fat
[54]. Furthermore, the quality, safety, and efficacy of sub-
stances obtained from the illicit market cannot be known,
with adulteration usually commonplace [2,63].
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Table 3 Use of non-AAS substances, reason(s)/motive(s) for use, and studies
Current polypharmacy (Combined with AAS) Lifetime polypharmacy (Ever use)
Substance Reason(s) for use Studies (First
author, reference)
Reason(s) for use Studies (First
author, reference)
Number of
studies
2,4-dinitrophenol NS Chandler [12] NS Chandler [12]; Dunn [15]; Hope [25]; Larance
[35]
4
Acetaminophen NS Strauss [55] NS Strauss [55] 1
Alcohol Better sleep and relaxation Chandler [12]; Hegazy [23];
Kanayama [28]; Kusserow [34];
Lundholm [37]; Malone [38];
Peters [46]; Perry [48]; Skårberg
[52-54]
Better sleep and relaxation Chandler [12]; Dunn [15]; Fudala [17]; Gruber
[21,22];
Hegazy [23]; Hoff [24]; Hope [25]; Kanayama
[26-28];
Katz [29]; Kusserow [34]; Malone [38];
Peters [46];
Perry [48]; Skårberg [52-54]; Tallon [56];
Wines [58]
23
Aminogluthimide Reducing receptors’ attraction
to cortisol
Peters [46] Reducing receptors’ attraction
to cortisol
Gruber [22]; Peters [46] 2
Amyl nitrate NS Chandler [12] NS Chandler [12] 1
Analgesics/opioids† Pain relief Ahlgrim [9]; Hegazy [23];
Kanayama [28]; Klötz [31];
Kusserow [34]; Lundholm [37];
Malone [38]; McBride [39];
Pappa [43]; Skårberg [53]
Pain relief Ahlgrim [9]; Fudala [17]; Gruber [22];
Hegazy [23];
Kanayama [26,28], Klötz [31]; Kusserow
[34]; Malone
[38]; McBride [39]; Pappa [43]; Rashid [49];
Skårberg
[53,54]
14
Anti-acne drugs† – – Combating acne Skårberg [54] 1
Antibiotics† Combating acne Peters [46] Combating acne Korkia [32]; Peters [46] 2
Anti-catabolics† NS Skårberg [53] Facilitating synthesis of hepatic
protein and nitrogen economy
Skårberg [53,54] 2
Anti-depressants† Combating side effects Klötz [31] Combating side effects, depression
relief, boosting levels of serotonin
and noradrenaline
Klötz [31]; Skårberg [54] 2
Anti-oestrogens† Burning fat, combating
gynecomastia,
reducing effects on oestrogen
Klötz [31]; Kusserow [34];
Peters [46]; Skårberg [53]
Combating gynecomastia, burning
fat, reducing effects on oestrogen
Gårevik [18]; Hope [25]; Klötz [31];
Korkia [32];
Kusserow [34]; Larance [35]; Peters [46];
Skårberg
[53,54]
9
Aromatase inhibitors† NS Chandler [12] NS Chandler [12] 1
Aspirin® NS Klötz [31]; Perry [45]; Skårberg
[53]; Strauss [55]
NS Klötz [31]; Larance [35]; Perry [45];
Skårberg [53];
Strauss [55]
5
Ben-Gay® NS Strauss [55] NS Strauss [55] 1
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Table 3 Use of non-AAS substances, reason(s)/motive(s) for use, and studies (Continued)
Benoxaprofen NS Strauss [55] NS Strauss [55] 1
Benzodiazepines† Better sleep, combating
side effects,
relaxation
Klötz [31]; Larance [35];
Lundholm [37]; McBride [39];
Skårberg [53]
Combating side effects, enhancing
sleep and relaxation, self-control,
sedation
Gårevik [18]; Klötz [31]; Larance [35];
Lundholm
[37]; Malone [38]; McBride
[39]; Skårberg [53,54]
8
Beta blockers† Burning fat Peters [46] Burning fat Peters [46] 1
Beta-2-agonists† – – NS Bilard [11] 1
Blood pressure
regulators†
NS Kusserow [34] Lower blood pressure Kusserow [34]; Skårberg [54] 2
Bronchodilators† Energy and boosting training Skårberg [53] Burning fat, energy and boosting
training, increasing strength
Skårberg [53,54] 2
Buprenorphine NS Skårberg [53] NS Skårberg [53]; Wines [58] 2
Caffeine Burning fat Klötz [31]; Pappa [43]; Perry
[45]; Peters [46]; Skårberg [53];
Strauss [55]
Burning fat Gruber [22]; Klötz [31]; Larance [35];
Pappa [43]; Peters [46]; Perry [45];
Skårberg [53]; Strauss [55]
8
Calcium – – NS Strauss [55] 1
Cannabis/cannabinoids Enhancing sleep, relaxation Chandler [12]; Kanayama
[27,28]; Klötz [31]; Kusserow
[34]; Lundholm [37]; Malone
[38]; McBride [39]; Pappa [43];
Peters [46]; Perry [48]; Skårberg
[53,54]
Enhancing sleep, relaxation Bilard [11]; Chandler [12]; Dunn [15];
Fudala [17]; Gruber [21,22]; Hoff [24];
Kanayama [27,28]; Klötz [31]; Kusserow
[34]; Larance [35]; Malone [38]; McBride
[39]; Pappa [43]; Peters [46]; Perry [48];
Rashid [49]; Skårberg [53,54]; Tallon [56]
21
Captopril NS Ahlgrim [9] NS Ahlgrim [9] 1
Carvedilol NS Ahlgrim [9] NS Ahlgrim [9] 1
Choline and inositol NS Strauss [55] NS Strauss [55] 1
Chromium picolinate Reducing body weight Peters [46] Reducing body weight Peters [46] 1
Clenbuterol Anabolic effects, burning fat,
removing skin fluid, weight loss
Chandler [12]; Gruber [21];
Kimergård [30]; Klötz [31];
Lenehan [36]; McBride [39];
Peters [46]; Wilson-Fearon [57]
Anabolic effects, burning fat,
removing skin fluid, weight loss
Chandler [12]; Gruber [20-22]; Hope [25];
Kimergård [30]; Klötz [31]; Korkia [33];
Larance [35]; Lenehan [36]; McBride [39];
Peters [46]; Tallon [56]; Wilson-Fearon [57]
14
Clomiphene citrate NS Chandler [12]; Moss [41,42];
Perry [45]
NS Chandler [12]; Moss [41,42]; Perry [45] 4
Cocaine Boosting training, burning fat,
increasing strength
Chandler [12]; Kanayama [28];
Larance [35]; Lundholm [37];
Malone [38]; Peters [46];
Skårberg [53,54]
Boosting training, burning fat,
increasing strength
Chandler [12]; Dunn [15]; Fudala [17];
Gårevik [18]; Gruber [21]; Hoff [24]; Hope
[25]; Kanayama [26-28]; Katz [29]; Larance
[35]; Lundholm [37]; Malone [38]; Peters
[46]; Rashid [49]; Skårberg [53,54]; Tallon
[56]
19
Codeine Boosting training Skårberg [53]; Strauss [55] Boosting training Skårberg [53]; Strauss [55] 2
Conjugated linoleic acid Burning fat Skårberg [53] Burning fat Skårberg [53] 1
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Table 3 Use of non-AAS substances, reason(s)/motive(s) for use, and studies (Continued)
Corticosteroids† NS Lenehan [36] NS Bilard [11]; Korkia [32]; Lenehan [36] 3
Creatine Enhancing the effects of training Klötz [31]; Skårberg [53]; Perry
[45]
Anabolic effects, endurance
booster,
enhancing the effects of training,
recovery aid
Davies [14]; Filiault [16]; Hoff [24];
Klötz [31]; Perry [45]; Skårberg [53,54]
7
Daonil® Increasing insulin release Peters [46] Increasing insulin release Peters [46] 1
Dehydroepiandrosterone
(DHEA)
– – NS Larance [35] 1
Diazepam – – NS Gårevik [18] 1
Dietary/nutritional
supplements†
Energy and boosting training,
nutrition
Pappa [43]; Perry [45]; Peters
[46]; Skårberg [53,54]; Strauss
[55]; Wilson-Fearon [57]
Energy and boosting training, anabolic
effects, endurance booster, nutrition,
recovery aid
Davies [14]; Filiault [16]; Gruber [21]; Korkia
[32]; Pappa [43]; Perry [45]; Peters [46];
Skårberg [53,54]; Strauss [55]; Tallon [56];
Wilson-Fearon [57]
12
Digoxin NS Ahlgrim [9] NS Ahlgrim [9] 1
Dimethyl sulfoxide NS Strauss [55] NS Strauss [55] 1
Diuretics† Combating side effects, masking
doping drugs, reducing fluid levels
Chandler [12]; Klötz [31];
Lenehan [36]; Pappa [43];
Peters [46]; Wilson-Fearon [57]
Combating side effects, masking doping
drugs, reducing fluid levels
Chandler [12]; Goldfield [19]; Hope [25]; Klötz
[31]; Korkia [32]; Larance [35]; Lenehan [36];
Pappa [43]; Peters [46]; Skårberg [54]; Tallon
[56]; Wilson-Fearon [57]
12
Electrolyte solution NS Strauss [55] NS Strauss [55] 1
Ephedra/Ephedrine Energy and boosting training,
enhancing weight loss
Chandler [12]; Kimergård [30];
Klötz [31]; McBride [39]; Perry
[45]; Peters [46]; Skårberg [53]
Energy and boosting training, burning
fat, enhancing weight loss, increasing
strength
Chandler [12]; Gårevik [18]; Gruber [20]; Gårevik
[18]; Hope [25]; Kimergård [30]; Klötz [31];
Larance
[35]; McBride [39]; Perry [45]; Peters [46];
Skårberg
[53,54]
14
Epinephrine NS Strauss [55] NS Strauss [55] 1
Erythropoietin (EPO) NS Pappa [43]; Schäfer [50] NS Hope [25]; Pappa [43]; Schäfer [50] 3
Esiclene – – NS Korkia [32] 1
Fat-loss agents† – – Burning fat Skårberg [54] 1
Furosemide Weight loss Ahlgrim [9]; Strauss [55] Weight loss Ahlgrim [9]; McKillop [40]; Strauss [55] 3
Gamma hydroxybutyrate
(GHB)
Enhancing sleep Chandler [12]; Klötz [31];
Skårberg [54]
Enhancing sleep Chandler [12]; Dunn [15]; Gruber [22];
Klötz [31]; Skårberg [54]
5
Genotropine NS Klötz [31] NS Klötz [31] 1
Glutamine NS Perry [45] NS Perry [45] 1
Growth hormone Anabolic effects and strength,
burning fat, weight loss
Chandler [12]; Kimergård [30];
Kusserow [34]; Lenehan [36];
Peters [46]; Skårberg [53,54];
Strauss [55]; Wilson-Fearon [57]
Anabolic effects, burning fat,
endurance
booster, recovery aid, weight loss
Chandler [12]; Filiault [16]; Fudala [17];
Gårevik [18];
Hope [25]; Kimergård [30]; Korkia [32,33];
Kusserow
18
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Table 3 Use of non-AAS substances, reason(s)/motive(s) for use, and studies (Continued)
[34]; Larance [35]; Lenehan [36]; Peters
[46]; Silvester
[51]; Skårberg [53,54]; Strauss [55]; Tallon [56];
Wilson-Fearon [57]
Growth hormone
releasing peptides†
NS Chandler [12] NS Chandler [12] 1
Hallucinogens† NS Larance [35]; Malone [38] NS Dunn [15]; Larance [35]; Malone [38] 3
Herbal products† NS Skårberg [53] Increasing strength Skårberg [53,54]
Heroin Enhancing sleep, pain relief Cornford [13]; Larance [35];
Skårberg [54]
Enhancing sleep, pain relief Gårevik [18]; Cornford [13]; Kanayama [27];
Larance
[35]; Skårberg [54]; Wines [58]
6
Human chorionic
gonadotropin (hCG)
Minimizing depressive symptoms
upon AAS cessation/withdrawal,
improving testosterone production,
preventing weight loss, stopping
testicular atrophy, increasing
strength
Chandler [12]; Kimergård [30];
Lenehan [36]; McBride [39];
Moss [41,42]; Perry [44]; Peters
[46]; Perry [47]; Korkia [32];
Wilson-Fearon [57]
Anabolic effects, increasing
testosterone production, minimizing
depressive symptoms upon AAS
cessation/withdrawal,
preventing weight loss,
stopping testicular atrophy,
increasing
strength
Chandler [12]; Fudala [17]; Gruber [22];
Gårevik [18];
Hope [25]; Kimergård [30]; Korkia [32];
Larance [35];
Lenehan [36]; McBride [39]; McKillop
[40]; Moss
[41,42]; Perry [44]; Peters [46]; Perry [47];
Wilson-Fearon [57]
17
Hydrochlorothiazide Weight loss Ahlgrim [9] Weight loss Ahlgrim [62] 1
Hydrocodone – – NS Wines [58] 1
Hydroxocobal amin Weight gain Peters [46] Weight gain Peters [46] 1
Inhalants† NS Larance [35] NS Dunn [15]; Larance [35] 2
Insulin Anabolic effects and strength,
burning fat, weight loss
Chandler [12]; Kimergård [30];
Klötz [31]; Peters [46]; Skårberg
[53,54]
Anabolic effects and strength,
burning fat, weight loss
Chandler [12]; Gårevik [18]; Hope [25];
Kimergård
[30]; Klötz [31]; Larance [35]; Peters [46];
Skårberg
[53,54]; Tallon [56]
10
Insulin-like growth factor
1 (IGF-1)
Anabolic effects and strength,
burning fat
Chandler [12]; Klötz [31];
Lenehan [36]; Peters [46];
Skårberg [53,54]
Anabolic effects and strength,
burning fat
Chandler [12]; Fudala [17]; Klötz [31];
Larance [35];
Lenehan [36]; Peters [46]; Skårberg [53,54]
8
Ketamine NS Chandler [12] NS Chandler [12]; Dunn [15] 2
Laxative – – NS Goldfield [19] 2
Levodopa NS Strauss [55] Increasing growth hormone Strauss [55]; Skårberg [54] 2
Lidocaine NS Strauss [55] NS Strauss [55] 2
Liothyronine NS Perry [45] NS Perry [45] 1
Lysergic acid
diethylamide (LSD)
NS Skårberg [54] NS Rashid [49]; Skårberg [54] 2
Mechano growth factor NS Chandler [12] NS Chandler [12] 1
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Table 3 Use of non-AAS substances, reason(s)/motive(s) for use, and studies (Continued)
Melanotan Boosting training, skin tanning Chandler [12]; Kimergård [30] Boosting training, skin tanning Chandler [12]; Hope [25]; Kimergård [30] 3
Mephedrone NS Chandler [12] NS Chandler [12] 1
Meth/amphetamine Alertness, boosting training,
burning fat, increasing aggression
during exercise, increasing strength,
psychological wellbeing
Chandler [12]; Hegazy [23];
Kimergård [30]; Larance [35];
Lundholm [37]; McBride [39];
Pappa [43]; Peters [46];
Skårberg [53,54]
Alertness, boosting training,
burning fat, increasing aggression
during exercise, increasing strength,
psychological wellbeing
Angoorani [10]; Chandler [12]; Gårevik
[18];
Hegazy [23]; Hoff [24]; Hope [25];
Kimergård
[30]; Larance [35]; Lundholm [37];
McBride [39];
Pappa [43]; Peters [46]; Skårberg [53,54];
Tallon [56]
15
Muscle oil (synthol) – – Anabolic effect Skårberg [54] 1
Muscle relaxing drugs† Combating side effects Klötz [31] Combating side effects Klötz [31] 1
Myoblast NS Klötz [31] NS Klötz [31] 1
Nalbuphine/nubain® NS Strauss [55]; Lenehan [36];
McBride [39]
Treating pain from weightlifting
injuries,
“anti-catabolic”, mental high
Gruber [22]; Hope [25]; Kanayama
[27]; Korkia
[33]; Lenehan [36]; McBride [39];
Strauss [55];
Wines [58]
8
Naproxen NS Strauss [55] NS Strauss [55] 1
Non-steroidal anti-
inflammatory drugs
(NSAIDs) †
– – Inflammation, pain, and fever relief Skårberg [54] 1
Oxycodone NS Strauss [55] NS Kanayama [27]; Strauss [55] 2
Peptide hormones† – – NS Bilard [11] 1
Phenylbutazone NS Strauss [55] NS Strauss [55] 1
Phosphodiesterase-5
inhibitors (PDE5i) †
– – NS Hope [25] 1
Piroxicam NS Strauss [55] NS Strauss [55] 1
Potassium NS Strauss [55] NS Strauss [55] 1
Potency/testicular
increasing drugs†
Combating side effects Klötz [31] Combating side effects Klötz [31] 1
Pregnyl® Improved testosterone production Peters [46] Improved testosterone production Peters [46] 1
Protein powder Enhancing effects of training,
increasing protein synthesis
Perry [45]; Skårberg [53,54] Enhancing effects of training,
increasing protein synthesis
Perry [45]; Skårberg [53,54] 3
Proviron® Hardiness, improved testosterone
production
Peters [46] Hardiness, improved testosterone
production
Peters [46] 1
Recovery drinks† – – Endurance booster, recovery aid Filiault [16] 1
Sedatives† NS Malone [38] NS Malone [38] 1
Sagoe
et
al.Substance
A
buse
Treatm
ent,Prevention,and
Policy
 (2015) 10:12 
Page
14
of
19
Table 3 Use of non-AAS substances, reason(s)/motive(s) for use, and studies (Continued)
Sildenafil/viagra®/cialis Enhanced sexual functioning Chandler [12]; Kimergård [30] Enhanced sexual functioning Chandler [12]; Gårevik [18]; Hope [25];
Kimergård [30]
4
Somatotropine NS Klötz [31] NS Klötz [31] 1
Spironolactone Weight loss Ahlgrim [9] Weight loss Ahlgrim [9] 1
Stimulants† NS Klötz [31]; Kusserow [34];
Malone [38]
Increasing strength, burning fat Fudala [17]; Klötz [31]; Kusserow [34]; Malone
[38]; Rashid [49]; Skårberg [54]
6
Suntan pills† NS Strauss [55] NS Strauss [55] 1
Tamoxifen Combating side effects Chandler [12]; Kimergård [30];
Lenehan [36]; McBride [39]
Combating side effects Chandler [12]; Gruber [22]; Kimergård [30];
Korkia [33]; Lenehan [36]; McBride [39];
Tallon [56]
7
Teroxin (T3) Preventing weight gain Peters [46] Preventing weight gain Peters [46] 1
Testosterone releasers/
boosters†
Combating side effects, increasing
hormone production
Skårberg [53] Combating side effects, increasing
blood serum levels of testosterone
or hormone production
Skårberg [53,54] 2
Thiazides† – – NS McKillop [40] 1
Thiomucase NS Wilson-Fearon [57] Burning fat Korkia [32,33]; Wilson-Fearon [57] 3
Thyroxine Burning fat,
increasing metabolism
Chandler [12]; Lenehan [36];
Peters [46]; Skårberg [54];
Strauss [55]
Burning fat, increasing metabolism Chandler [12]; Gruber [22]; Hope [25]; Korkia
[32]; Larance [35]; Lenehan [36]; McKillop
[40]; Peters [46]; Skårberg [54]; Strauss [55]
10
Tobacco NS Malone [38]; Perry [48]; Pope
[47]
NS Malone [38]; Perry [48]; Pope [47] 3
Torsemide NS Ahlgrim [9] NS Ahlgrim [9] 1
Triacana – – NS Korkia [33] 1
Yohimbine NS Perry [45] NS Gruber [22]; Perry [45] 3
Other IPEDs, licit and
illicit substances
NS Kanayama [28]; Klötz [31];
Kusserow [34]; Perry [48];
Skårberg [52]
NS Gruber [20,21]; Hoff [24]; Hope [25];
Kanayama [26,28];
Klötz [31]; Kusserow [34]; Perry [48];
Skårberg [52,54];
Wines [58]
IPEDs: Image and performance-enhancing drugs.
NS: Not specified.
†Substance class - not specified.
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Table 4 Groups of non-AAS substances used by AAS users
Group Examples Purpose(s)
Analgesics/non-steroidal anti-
inflammatory drugs/opioids
Acetaminophen, aspirin®, Ben-Gay®, benoxaprofen, buprenorphine, codeine, corticosteroids†,
heroin, hydrocodone, lidocaine, muscle oil (synthol) and muscle relaxing drugs†, nalbuphine/
nubain®, naproxen, oxycodone, phenylbutazone, piroxicam
Relieving inflammation, pain, and fever
Anti-oestrogens Aminogluthimide, aromatase inhibitors†, clomiphene/clomid, proviron®, tamoxifen Improved testosterone production, burning body fat,
reducing the effects of AAS on oestrogens, and dealing
with gynecomastia
Cardiovascular drugs Beta-2-agonists†, beta-blockers†, captopril, carvedilol, digoxin, thiazides† Lowering blood pressure, reducing risk of infarction, and
burning body fat
CNS depressants Alcohol, benzodiazepines†, buprenorphine, cannabis/cannabinoids, diazepam, gamma
hydroxybutyrate (GHB), heroin, hydrocodone, ketamine, oxycodone
Improving sleep, relaxation, and dealing with side effects
of AAS use such as gynecomastia
CNS stimulants Amyl nitrate, caffeine, cocaine, ephedrine, epinephrine, mephedrone, meth/amphetamine,
yohimbine
Alertness, boosting training, burning body fat, increased
aggression and strength, and psychological wellbeing
Cosmetic drugs Anti-acne drugs†, esiclene, melanotan I, suntan pills, thiomucase Curing acne, skin tanning, and enhancing physical
appearance
Dietary/nutritional supplements Calcium, choline and inositol, chromium picolinate, conjugated linoleic acid, creatine,
electrolyte solution, glutamine, hydroxocobal amin, piroxicam, potassium, protein powder
For essential nutrients to supplement the diet and combat
the risk of illness
Diuretics Furosemide, hydrochlorothiazide, spironolactone, torsemide Increasing strength, masking AAS and other doping drugs,
burning body fat, and reducing levels of body fluid
Fat burning/weight loss drugs 2,4-dinitrophenol (DNP), anti-oestrogens†, beta blockers†, bronchodilators†, caffeine, chromium
picolinate, clenbuterol, cocaine, conjugated linoleic acid, ephedrine, hydrochlorothiazide, insulin**,
laxatives††, liothyronine, melanotan II, meth/amphetamine, spironolactone, teroxin (T3), thiomucase,
thyroxine, triacana, yohimbine
Suppression of appetite, increased metabolism, and reduced
absorption of body fat
Muscle/strength-enhancement
drugs (non-hormone)
Amphetamine/meth, anti-catabolics†, glutamine, bronchodilators, chromium picolinate, clenbuterol,
creatine, ephedrine, herbal products††, hydroxocobal amin (B12), myoblast, muscle oil (synthol),
protein powder, recovery drinks†
Enhancing the size and structure of muscles as well as
boosting strength
Muscle/strength-enhancement
hormones††
Dehydroepiandrosterone (DHEA), erythropoietin (EPO), genotropine, growth hormone, growth
hormone releasing peptide (GHRP), human chorionic gonadotropin (hCG), insulin-like growth
factor 1 (IGF-1), insulin, levodopa, mechano growth factor, pregnyl®, prohormones†, proviron®,
somatotropine
Enhancing the size and structure of muscles as well as
boosting strength
Recreational substances/drugs Alcohol, buprenorphine, cannabis/cannabinoids, cigarettes/tobacco methamphetamine, blood
pressure regulators†, caffeine, cocaine, ecstasy, hallucinogens†, heroin, hydrocodone, ketamine,
lysergic acid diethylamide (LSD), sedatives†, tetrahydrocannabinol
Enhancing sleep, relaxation, and psychological wellbeing
Sexual enhancement drugs Anti-oestrogens†, human chorionic gonadotropin (hCG), melanotan II, phosphodiesterase-5
inhibitors (PDE5i), sildenafil/cialis®, yohimbine
Dealing with testicular atrophy, improved sexual desire or
arousal and boosting erectile functioning
CNS: Central nervous system.
†Substance class - not specified.
††Some are used for direct muscle enhancing properties and others for counteracting shut-down of endogenous testosterone production.
**Skårberg [54].
There may be overlap between classes (e.g. CNS depressants may be used for promoting sleep and for analgesic properties).
Some of the drugs do not have well documented efficacy for their alleged motives for use.
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Implications for policy and practice
The present study has highlighted various licit and illicit
substances used by AAS users. Evidence abounds that
some of the substances identified in our study, especially
dietary and nutritional supplements, may be contami-
nated with AAS and other pharmacological elements
thus, potentially, playing a role in the decision to initiate
AAS use [2,64-67]. Preventive efforts should therefore
highlight the potential role licit and illicit substance use,
especially dietary and nutritional supplement use, may
play in the initiation of AAS use as well as the role AAS
use may potentially play in the use of other substances,
together with the potential negative consequences indi-
viduals who engage in such behavior may encounter.
AAS-associated polypharmacy is dangerous for several
reasons. First, it has been associated with violent and crim-
inal behavior as well as various forms of pathology and
mortality [68-70]. Second, chemical interactions from
AAS-related polypharmacy may have adverse psychophys-
ical effects on individuals engaged in such behavior. Thus,
the main and combined effects of the use of these sub-
stances must attract the attention of clinicians, policy-
makers and public health officials. Indeed, physicians may
inadvertently administer medication to AAS-using poly-
drug users thereby triggering unintended adverse chemical
interactions that may be harmful to AAS-using patients.
Accordingly, gathering correct and comprehensive sub-
stance use histories of AAS users is important in the
effective pharmacological and psychological treatment of
AAS users [67,71] as such information may guide clini-
cians in the diagnosis and prescription of ‘safe’ drugs dur-
ing treatment.
Additionally, most AAS users obtain the substances
identified in the present study from the illicit market [1,2].
Because many of these substances are controlled or illegal
[2], they may be produced in unsterile ‘underground
laboratories’ leading to inadvertent and sometimes delib-
erate incorrect dosing, substitution of ingredients and
contamination with additional pharmaceuticals, toxic che-
micals and pathogens. Furthermore, some users resort to
unsterile injection equipment for the administration of these
products, resulting in injecting site injuries as well as bacter-
ial and fungal infection [72] and the potential transmission
of blood borne viruses such as hepatitis B/C and HIV [25].
Stakeholders must take our findings into consideration in
the development of preventive and therapeutic interventions
for AAS users. There is also the need for the strengthening
of harm reduction interventions to combat the harmful
consequences of AAS-related polydrug use.
Implications for research
There is the need for further investigations to elucidate
better the pathway to AAS-associated polysubstance use.
Further studies are also necessary to examine the main
and complementary enervating consequences of the use
of different dosages of these varied substances, plus their
addictive potential and trajectories. Moreover, there is a
dearth of knowledge regarding the spread of these sub-
stances due to the fact that most of these substances are
relatively new. So far most focus has been directed to-
ward AAS in particular. Thus, the use of ancillary and
associated substances has mainly escaped the attention
of clinicians, public health officials, policymakers, and
researchers [2]. There is therefore the need for studies
examining the emergence of these substances in the
pharmacopoeia of substance users as well as their diffu-
sion into other substance-using populations.
There is the need for the collection and analysis or test-
ing of these substances, to ascertain their content and po-
tential contaminants. Additionally, apart from the Iranian
study [10], all studies were conducted in Western coun-
tries. Nonmedical AAS use is a global public health prob-
lem [4] and researchers are encouraged to extend their
investigations to non-Western nations. Finally, investiga-
tions of AAS-associated polypharmacy must be a continu-
ous process requiring updates as evidence accumulates.
Strengths and limitations
As far as we are aware, the present study is the pioneer-
ing international systematic review and synthesis of
qualitative studies on AAS use and polypharmacy. The
inclusion of both peer-reviewed and grey literature, as
well as literature published before 1995 and after 2009,
also distinguishes this review from a previous review [3].
The present study also has some limitations that ought to
be taken into consideration when interpreting our find-
ings. First, due to the nature of the present study, it was
not statistically possible to establish ‘gateway’ or causal as-
sociations between AAS use and use of the other sub-
stances. In addition, we were unable to establish the
prevalence of the use of these substances by AAS users.
Third, some of the studies included in the present study
did not specifically investigate AAS users’ intake of other
licit and illicit substances. Although these studies present
very useful data in respect of the present study, it is plaus-
ible that these studies do not present a comprehensive
picture of the variety of substances ingested by AAS users.
Similarly, the case reports included in the present study
may have been published because they are ‘extraordinary’
and may therefore not be representative of the ‘typical’
AAS user. With the relative paucity of literature in this
field [73], the inclusion of these studies is in our view still
defendable. Finally, there is the possibility that our exclu-
sion of non-English language literature may have biased
our results. It should be noted however that this very
common practice in terms of reviews and meta-analyses
might not necessarily affect findings [62].
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Conclusions
Our findings corroborate previous suggestions of associa-
tions between AAS use and the use of a wide range of
other licit and illicit substances. AAS-related polypharmacy
has potential serious harmful effects for persons who en-
gage in such behavior, which should be of serious public
health concern. Clinicians, policymakers, researchers, and
public health workers dealing with AAS users must be
educated about these issues. Importantly, efforts must
be intensified to combat the debilitating effects of AAS-
concomitant polypharmacy. Furthermore, there needs
to be ongoing research to investigate trends in AAS use
and polypharmacy.
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